Axiom Catalyst

In Episode One of The Axiom Catalyst: Market Access Series, we sit down with Omar Ali, Head of Payers at Verpora and former adviser to NICE, to unpack what MFN really means for the industry.

Omar walks us through the potential global ripple effects, the biggest unknowns, and the practical steps companies can take to prepare as the policy landscape continues to shift.

Asia’s oncology landscape is changing fast.

In this latest Axiom Catalyst episode, the #AxiomThinkTank India team and top regional experts, including 𝗗𝗿. 𝗞𝗼𝗵𝗲𝗶 𝗦𝗵𝗶𝘁𝗮𝗿𝗮, who focuses on innovative therapies for gastrointestinal cancers, and Dr. Vanita Noronha, who specializes in enhancing treatment options for geriatric oncology patients, dig into the most exciting #ESMO2025 breakthroughs - from novel immunotherapies to ADCs - and explore how they could reshape treatment access and standards across Asia.

#ESMO25 #OncologyInsights #AsiaOncology #OncologyInAsia

In this episode of the Axiom Catalyst Life Sciences Podcast, Jai Bains speaks with Dr. Gayathri Swaminath, VP of Cardiovascular at Pioneering Medicines, about the evolving role of pre-emptive medicine in cardiometabolic renal disease, with a focus on chronic kidney disease. From redefining early intervention to exploring the role of biomarkers, and multi-omics, this conversation dives into the science, system barriers, and future outlook for tackling CKD earlier and more effectively.

Listen in to learn more!

Chiranth Achar discussed the rare disease landscape in India with Prasanna Shirol, Co-founder & Director of the Organization for Rare Diseases India.

The ORDI would like to make listeners aware of the significant work done by them in aid of rare disease patient in India. This includes India’s First Rare Disease Helpline: (+91) 8892 555 000, the Savemylife patient support program, Racefor7 a symbolic 7,000 meter race to raise rare disease awareness and drive outreach across India to connect all stakeholders, and significant collaboration with international bodies such as Rare Diseases International.

Dan Simpson connected with Prof. Dave Pearce, Chair of the International Rare Diseases Research Consortium (IRDiRC) and professor of pediatric rare diseases. Prof. Pearce speaks passionately about the needs of rare disease patients around the world, and how the IRDiRC brings together funding agencies, companies, patient advocate groups, and other organization from approximately 80 countries to address patient care through a number of core initiatives.

The IRDiRC is a global collaborative initiative launched in 2011 by the European Commission and the U.S. National Institutes of Health to tackle rare diseases through research and accomplish the vision to enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention. Dr. Pearce is an internationally recognized leader in a number of areas. He has published over 100 research papers on Batten disease, founded an international registry for rare diseases known as the Coordination of Rare Diseases at Sanford (CoRDS), and has served on numerous NIH review committees, rare disease advisory boards and has organized rare disease workshops. 

Marissa McPhillips met Michelle, in her capacity as CEO of Alltrna, for a constructive conversation around the critical role industry plays in developing innovative treatments for rare disease. We heard how it takes an environment that supports innovation, with incentives, novel clinical trial designs, and other enabling regulations – with Michelle urging the rare disease community to continue to push for these things.

For more information about Alltrna and how they are scaling rare disease drug development by pioneering tRNA medicines to treat Stop Codon Disease, check out their LinkedIn page, YouTube channel, and X account (formerly Twitter).

Seona Lee and Dr Brandsema, pediatric neurologist at CHOP, discuss his firsthand specialist physician’s experience in treating rare disease patients – including the challenges, progress and hope for 2025. Listen in for some inspiring patient stories.

Check out the work CHOP is doing to improve the lives of patients with Duchenne’s (DMD) here.

What does it take to navigate through the complex question of when and with whom to partner for a companion diagnostic?

Join us in yet another invigorating episode at #AxiomCatalystPodcast where Anne Cherry hosts top industry experts, Kara O'Brien and Tricia Carrigan to share invaluable insights on:

✅ Choosing the right technology

✅ Deciding between in-house development and partnerships

✅ Timing your collaborations strategically

✅ Selecting the ideal diagnostic partner

Subscribe now so you don't miss a beat from the #AxiomTable

#CompanionDiagnostics #PrecisionMedicine #PharmaInnovation #PharmaStrategy

Go-to-Market Strategies: In this dynamic panel discussion moderated by the Managing Principal of Axiom Healthcare Strategies, experts dive into innovative strategies that are reshaping how pharma companies bring new therapies to market. From leveraging advanced data analytics to navigating regulatory pathways, the conversation covers key approaches to speed up launches and maximize impact for patients in oncology and rare diseases.

To learn more about how we galvanize innovative product launches across oncology and rare diseases, reach out to our Managing Director, Jon Yoder, at [email protected]

Catch the full conversation here: https://www.youtube.com/watch?v=_-oWLf_YeJo

#HealthcareInnovation #ProductLaunch #LifeSciences #AxiomSummit #AxiomThinkTank

Industry at a Crossroads – Presented by Jon Yoder, Managing Director of Axiom Healthcare Strategies, this insightful session explores the pivotal challenges and opportunities shaping the future of the healthcare industry. Don’t miss these strategic perspectives on where the industry is headed.

To learn more about the future of the biotech industry and its investor ecosystem, reach out to Jon at [email protected]

Watch the full session here: https://www.youtube.com/watch?v=j9ry7pvb_1I

#HealthcareIndustry #Strategy #AxiomSummit #Innovation